Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Buys $256,050.00 in Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly acquired 45,000 shares of the stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the purchase, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $7.14 on Friday. The stock’s fifty day moving average price is $5.74 and its two-hundred day moving average price is $9.50. Enanta Pharmaceuticals, Inc. has a 52-week low of $4.71 and a 52-week high of $17.80. The company has a market cap of $152.32 million, a price-to-earnings ratio of -1.30 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. On average, equities analysts predict that Enanta Pharmaceuticals, Inc. will post -5.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ENTA has been the topic of a number of research analyst reports. Robert W. Baird decreased their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ENTA. US Bancorp DE lifted its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at $26,000. Tower Research Capital LLC TRC lifted its stake in shares of Enanta Pharmaceuticals by 46.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 2,274 shares during the period. Intech Investment Management LLC acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at $122,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.